title: Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
abstract: OBJECTIVE
  To compare treatment results with use of nab-paclitaxel in routine clinical practice with data obtained from clinical trials.
  
  
  METHODS
  A retrospective chart review of all 36 patients with metastatic breast cancer treated with nab-paclitaxel was performed. Nab-paclitaxel was given weekly and usually started at 150 mg/m(2).
  
  
  RESULTS
  Thirteen (36.1%) patients received nab-paclitaxel as first-line, seven (19.4%) as second-line and 16 as third- or further line treatment. Overall, the response rate was 9.7%, disease control rate 64.5%, median progression-free survival 7.5 months and median overall survival 14.2 months. The most frequent non-hematological toxicities of grade 3 or more were fatigue (27.8%), dyspnea, rash and arthalgia (all 5.6%). Six (16.7%) patients developed peripheral neuropathy of grade 2 or more. Incidence of neutropenia grade 3 or more was 41.7% with no case of febrile neutropenia.
  
  
  CONCLUSIONS
  According to our experience, weekly nab-paclitaxel is effective and tolerable, with results at least comparable to those from the prospective clinical trials.
authors.affiliation: National Center for Tumor Diseases, University Hospital, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany. andreas.schneeweiss@med.uni-heidelberg.de
authors.forename: Julia
authors.initials: J
authors.lastname: Aigner
authors.forename: Frederik
authors.initials: F
authors.lastname: Marmé
authors.forename: Katharina
authors.initials: K
authors.lastname: Smetanay
authors.forename: Florian
authors.initials: F
authors.lastname: Schuetz
authors.forename: Dirk
authors.initials: D
authors.lastname: Jaeger
authors.forename: Andreas
authors.initials: A
authors.lastname: Schneeweiss
mesh_terms: D000328:Adult; D000368:Aged; D000418:Albumins / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D017239:Paclitaxel
keywords: Metastatic breast cancer; chemotherapy; nab-paclitaxel